Ovid Therapeutics Inc (OVID) concluded trading on Wednesday at a closing price of $0.31, with 4.3 million shares of worth about $1.33 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.17% during that period and on June 25, 2025 the price saw a gain of about 4.24%. Currently the company’s common shares owned by public are about 71.11M shares, out of which, 59.51M shares are available for trading.
Stock saw a price change of 4.00% in past 5 days and over the past one month there was a price change of 10.23%. Year-to-date (YTD), OVID shares are showing a performance of -59.68% which decreased to -66.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $1.47 during that period. The average intraday trading volume for Ovid Therapeutics Inc shares is 623.93K. The stock is currently trading 4.14% above its 20-day simple moving average (SMA20), while that difference is up 4.03% for SMA50 and it goes to -56.73% lower than SMA200.
Ovid Therapeutics Inc (NASDAQ: OVID) currently have 71.11M outstanding shares and institutions hold larger chunk of about 54.79% of that.
The stock has a current market capitalization of $22.36M and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$0.35 in the same period. It has Quick Ratio of 4.93 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OVID, volatility over the week remained 5.56% while standing at 4.81% over the month.
Analysts are in expectations that Ovid Therapeutics Inc (OVID) stock would likely to be making an EPS of -0.15 in the current quarter, while forecast for next quarter EPS is -0.14 and it is -0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.16 which is -0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -67.48% while it is estimated to decrease by -5.67% in next year.
Coverage by B. Riley Securities stated Ovid Therapeutics Inc (OVID) stock as a Buy in their note to investors on April 30, 2024, suggesting a price target of $9 for the stock. On April 29, 2024, H.C. Wainwright Initiated their recommendations, while on April 05, 2024, Wedbush Initiated their ratings for the stock with a price target of $8. Stock get a Buy rating from BTIG Research on December 21, 2023.
